| Name | Title | Contact Details |
|---|
Cedar provides a smarter way for hospitals, health systems and medical groups to manage the patient payment ecosystem. Our platform delivers modern intelligence to alleviate collections challenges, dramatically improve billing operations and ensure a personalized billing experience for patients. Most revenue cycle solutions today look at only one or two transactional aspects of patient payments. We believe that the focus instead should be on improving the overall experience of patient billing and engagement. Together with the leading medical groups and hospitals across the country, we are elevating the patient payment experience.
CommunityCare, one of the largest health care companies in Oklahoma, is locally owned and operated by Saint Francis Health System and St. John Health System in Tulsa. CommunityCare offers a wide variety of group and individual products, including HMO, HRA, POS and PPO plans, Medicare Advantage plans, Medicare supplement plans, an employee assistance program and a workers` compensation plan. CommunityCare is proud to be Oklahoma`s best choice for health care.
Person Memorial Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Person Memorial Hospital is based in Roxboro, NC. You can find more information on Person Memorial Hospital at www.personhospital.com
Women In Need is a Portland, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.